An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
male and non-pregnant or nursing female patients \>=18 years of age;
body weight \<=150kg;
moderate to severe active RA (DAS28 \>=3.2) of \>=6 months duration;
on \>=1 non-biologic DMARDs at a stable dose for a period of \>= 8 weeks prior to start of treatment;
inadequate clinical response to a stable dose of non-biologic DMARD or anti-TNF therapy;
if receiving oral corticosteroids, the dose must have been stable for at least 25 of 28 days prior to start of treatment.
You may not be if
major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following enrollment;
rheumatic autoimmune disease other than RA;
prior history of, or current inflammatory joint disease other than RA;
functional class IV as defined by the ACR Classification of Functional Status in RA.
Clareo Health | An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.
